** Shares of Australia's InhaleRx IRX.AX rise as much as 7.7% to A$0.027, posting their biggest intraday pct gain since November 20
** Medical device maker gets A$12.6 million ($8.32 million)in additional funding to support development of SRX-25, an oral fixed-dose combination therapy targeting treatment-resistant depression
** Stock has fallen 19.4% this year, including day's moves
($1 = 1.5145 Australian dollars)
(Reporting by Roshan Thomas in Bengaluru)
((Roshan.Thomas@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.